Looking back at two treatment approaches for multiple sclerosis in people over 50
Reviews past records of two treatment approaches for multiple sclerosis in older adults.
Plain-language title generated from the registry record
Registry title: Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
Key facts
- Where
- Strasbourg, FranceSee the site
Where in France
- Centre d'Investigation Clinique - CHU de Strasbourg - FranceStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07313462
- Record updated
- 2 January 2026
- Original description
The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.Read full original descriptionShow less
Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50
The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.
Inclusion: Patients with RRMS onset after age 50; Patients who started their first disease-modifying therapy within 2 years of the first symptoms; Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon); Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine).
Exclusion: Patients with early progressive MS.